Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results | News

MISSISSAUGA, ON, Could 26, 2022 /PRNewswire/ – Covalon Technologies Ltd. (the “Organization” or “Covalon”) (TSXV: COV) (OTC: CVALF), an sophisticated medical technologies business, will release its Q2 Fiscal 2022 economical effects on Monday May perhaps 30^th, 2022, in advance of marketplaces open up. A meeting simply call and webcast to explore the economical success will be held on Monday Could 30^th, 2022, at 9:00am EST.

To watch, listen to, and participate in the are living webcast, please abide by the url under:

https://produceredition.webcasts.com/starthere.jsp?ei=1551026&tp_critical=74c818f1fa

To hear and participate by using the conference get in touch with, please dial:

North American Toll-Totally free: 1-888-664-6392

Local (Toronto): 416-764-8659

Affirmation Quantity: 10020730

Members will be capable to request queries of Corporation management during the Q&A portion of the meeting simply call possibly by inquiring them on the get in touch with or by submitting them making use of the chat purpose on the webcast.

A recording of the call will be accessible by contacting 1-888-390-0541 or 416-764-8677 and entering the encore replay entry code 020730# until June 13^th, 2022. A recording of the call will also be offered on www.covalon.com below Information & Activities on the Traders tab.

Copies of Covalon’s fiscal statements and MD&A can be attained on SEDAR at www.sedar.com and under Sedar Filings on the Traders tab of Covalon’s internet site.

About Covalon

Covalon Technologies Ltd. is a researcher, developer, producer, and marketer of patent-protected healthcare products and solutions that enhance affected person outcomes and conserve lives in the parts of superior wound treatment, infection management and surgical processes. Covalon leverages its patented clinical technologies platforms and know-how in two approaches: (i) by creating products that are offered under Covalon’s identify and (ii) by producing and commercializing clinical products and solutions for other clinical corporations underneath enhancement and license contracts. The Firm is mentioned on the TSX Undertaking Trade, acquiring the symbol COV and trades on the OTQX Market below the symbol CVALF. To discover more about Covalon, visit our website at www.covalon.com.

Neither TSX Enterprise Exchange nor its Regulation Companies Company (as that time period is described in the insurance policies of the TSX Undertaking Exchange) accepts duty for the adequacy or accuracy of this launch.

This news release has ahead-seeking statements which reflect the Firm’s current expectations with regards to potential occasions. The ahead-wanting statements are generally, but not normally, recognized by the use of words these as “look for”, “anticipate”, “system, “estimate”, “assume”, “intend” and statements that an party or final result “might”, “will”, “must”, “could” or “could” happen or be accomplished and other related expressions. These ahead-hunting statements entail threat and uncertainties, such as the trouble in predicting products approvals, acceptance of and demands for new products and solutions, the impression of the products and pricing techniques of rivals, delays in establishing and launching new goods, the regulatory setting, fluctuations in operating results, the effect and timing of COVID-19 on working functions and market place circumstances,  and other risks, any of which could induce benefits, overall performance, or achievements to differ materially from the results discussed or implied in the forward-hunting statements. Numerous threats are inherent in the marketplace some others are far more unique to the Corporation. Investors need to consult the Firm’s ongoing quarterly filings for further info on dangers and uncertainties relating to these forward-searching statements. Investors must not put undue reliance on any forward-wanting statements. The Enterprise assumes no obligation to update or alter any ahead-searching statements irrespective of whether as a outcome of new facts, additional occasions or in any other case.

Check out original content to download multimedia:https://www.prnewswire.com/news-releases/covalon-announces-conference-phone-to-discuss-2nd-quarter-fiscal-2022-money-final results-301555723.html

Source Covalon Technologies Ltd.